Literature DB >> 785988

Disopyramide: serum level and arrhythmia conversion.

A P Niarchos.   

Abstract

The response of arrhythmias to oral disopyramide in relation to its serum levels has been documented. Disopyramide (100 mg.) was given orally, 6 or 8 hourly, to 16 patients with coronary or hypertensive heart disease who developed acute but stable cardiac arrhythmias (20 episodes) which persisted, despite bed rest and sedation with intravenous diazepam or diamorphine. Blood was taken when arrhythmia conversion was observed and the serum disopyramide levels were estimated by gas chromatography. Over-all control of arrhythmias was achieved in 13 (82 per cent) patients within 24 hours. Disopyramide-serum levels were as follows: effective for atrial arrhythmias, 2.80 to 3.18 mug per milliliter, and 3.27 to 7.48 mug per milliliter for ventricular; mean effective levels for all arrhythmias, 3.69 mug per milliliter; mean ineffective levels, 2.39 mug per milliliter (p less than 0.01). Side effects (prolongation of PR and QTc, fall of diastolic BP, urine retention) were observed with serum levels of 3.61 to 7.48 mug per milliliter (mean, 5.54 mug per milliliter) but they were not troublesome clinically. It is concluded that disopyramide is effective and safe with serum levels ranging from 2.39 to about 3.60 mug per milliliter, and this can be maintained with 100 mg., 8 hourly. The drug, however, should be given with caution to patients with severe myocardial disease or low arterial pressure and in the presence of an abnormal ECG.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 785988     DOI: 10.1016/s0002-8703(76)80403-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  28 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 3.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

4.  Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers.

Authors:  H Echizen; M Nakura; T Saotome; S Minoura; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

5.  Haemodynamic effects of disopyramide in patients after open-heart surgery.

Authors:  N Naqvi; D S Thompson; W E Morgan; B T Williams; D J Coltart
Journal:  Br Heart J       Date:  1979-11

6.  Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide.

Authors:  J Hulting; B Jansson
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

7.  Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.

Authors:  M L Aitio
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 9.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Disopyramide pharmacokinetics during recovery from myocardial infarction.

Authors:  S M Bryson; C J Cairns; B Whiting
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.